The Clinical Observation On Treating Incoordination Between The Liver And Stomach Type Of Stomachache With Shugan Hewei Zhitong Prescription

ObjectIncoordination between liver and Stomach Type of Stomachache ofclinical efficacy and safety, preliminary study on Shugan Hewei ZhitongPrescription treatment incoordination between mechanisms byobserving Shugan Hewei Zhitong Prescription treatment, provide thebasis for clinical use.Methods1.Cases collected：120patients, all patients selected a Wuhanhospital outpatient or inpatient department in line with epigastric painTCM diagnostic disease duration,criteria,liver and Stomachachegroups in gender and also met the inclusion criteria, TCM isincoordination between liver and the patient’s, clinical safe questionsand record.2.Grouping method：120patients were randomly divided into atreatment group and the control group,60cases general condition ineach group.Two groups of patients in terms of gender, age, diseaseduration, disease severity, Hp-positive rate, endoscopyand biochemical examination have no significant difference (P>0.05).3.Treatment：The treatment group is t of treated with Shugan Hewei Zhitong Prescription Daily1agent served three times, each200ml of half an hour before meals, clothing, for6weeks.The control groupwas treated with Shugan Hewei pill two times a day, each9g, half anhour before taking the course of six weeks.During the treatment, thedrug treatment of the disabled with the disease, and the influential drugtest, prohibit tobacco and alcohol, eat spicy greasy food, pay attentionto rest.4.Observation index：Before and after treatment for a medicalexamination, including physical examination, blood analysis, urineanalysis, stool examination three routine examination, ECG, liver andkidney function,14C-UBT, endoscopy and other tests; observed beforeand after treatment in patients with clinicalimprovement of symptoms,TCM syndromes;3months after the end of the experiment, carried outa follow-up to observe the progression of the disease after the testcase.Result1.ordinary circumstances：Two groups of patients in the testingprocess does not appear significant adverse reactions after treatmentmedical examination, blood and urine feces three conventionalelectrocardiogram, liver and kidney function tests, and no abnormalchange.2.Comparison of two groups of patients before and after symptomscore:Compared with before treatment, the two groups of patients withthe symptom score has reduced to varying degrees. Compared with thecontrol group, epigastric pain, flank pain, belching, hiccups, epigastricdiscomfort,sour regurgitationthe5symptoms improvement, thetreatment group than the control group (P <0.01); improvement of thesymptoms of poor appetite,the treatment group was less favorable than the control group (P<0.05); emotional depression, sighing the twosymptomatic improvement, there was no significant difference (P>0.05).3.Comparison of TCM syndrome total score of the two groupsbefore and after treatment:Before treatment, the two sets of symptomstotal score compared no significant difference (P>0.05); compared withbefore treatment, the total score of the two sets of symptoms aftertreatment was significantly lower (P<0.05); compared with the controlgroup, treatment group symptom total score reductionvery significant(P<0.01).4.Comparison of the efficacy of TCM treatment group twocases:Treatment group,16patients were cured,25cases markedlyeffective in11cases,7cases, the cure rate was26.67%, total effectiverate was88.33%; controlled clinical cure in5cases,14cases markedlyeffective in19cases, ineffective in22cases, the cure rate of8.33%, thetotal efficiency of63.33%. Two groups of patients with total efficiencyand a significant difference (P<0.05), the treatment group than thecontrol group.5.Comparison of Hp eradication rate of two groups of patientsafter the treatment:The treatment group of41cases of Hp positivepatients, negative in21cases after treatment, the eradication rate was51.22%; the control group of40cases of Hp positive patients, negativein14cases after treatment, the eradication rate of35%. The rate of Hperadication rate of treatment group was higher than that of control group(P<0.05).6.The long-term curative effect observation:Three months after theend of treatment of two groups of patients were followed up,16werecured recurrence in5, the recurrence rate was31.25%,44people not tocure the increase of4people, accounting for9.09%; the control group of5cured recurrence in3, the recurrence rate was60%,55were notcured increase of9people, accounting for16.36%. The recurrent ratein the treatment group and the aggravation N ratio was lower than thatof the control group (P<0.05).Conclusion1.Shugan Hewei Zhitong Prescription treatment of incoordinationbetween liver and stomach Type of Stomachache efficacy exact, cansignificantly improve the clinical symptoms of the patients, and noadverse reactions in the clinical use of the process.2. Shugan Hewei Zhitong Prescription contrast Shugan Hewei pillhas obvious advantages in improvement in symptoms,TCM syndromecurative effect,Hp eradication effect,long-term efficacy.3.Shugan Hewei Zhitong Prescription for effective pathogenesischaracteristics and drove reactions permit group clinical use Westernmedicine is safe and worthy of clinical use.